Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae Stock Down 4.5 %
Shares of Invitae stock opened at $4.25 on Thursday. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.42 and a quick ratio of 6.07. The company has a 50-day moving average of $2.80 and a 200 day moving average of $5.58. The firm has a market cap of $999.90 million, a price-to-earnings ratio of -0.32 and a beta of 1.82. Invitae has a 1 year low of $1.83 and a 1 year high of $32.93.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on NVTA. Raymond James cut shares of Invitae from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 21st. Benchmark lowered shares of Invitae from a "buy" rating to a "hold" rating in a report on Tuesday, July 19th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. lowered shares of Invitae from a "neutral" rating to an "underweight" rating in a report on Wednesday, August 10th. Finally, SVB Leerink lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 19th. Two research analysts have rated the stock with a sell rating and nine have given a hold rating to the company's stock. According to data from MarketBeat.com, Invitae has an average rating of "Hold" and an average price target of $13.56.